Pharmaceutical savings after gastric bypass surgery.

Autor: Monk JS Jr; Department of Surgery, York Hospital, York, PA 17405, USA. jmonk@wellspan.org, Dia Nagib N, Stehr W
Jazyk: angličtina
Zdroj: Obesity surgery [Obes Surg] 2004 Jan; Vol. 14 (1), pp. 13-5.
DOI: 10.1381/096089204772787220
Abstrakt: Background: Clinically severe obesity (CSO) is a surgically treated disease. The Roux-en-Y gastric bypass (RYGBP) has been used to treat patients with CSO and has resulted in an improvement in co-morbidities. We speculated that after a period of weight loss, patients would require less medication, resulting in cost-savings to both the patient and the insurance company, as well as an overall gain in health.
Method: A retrospective study was performed which involved the first 100 patients who had undergone RYGBP at a community-teaching hospital. Analysis of the data was conducted by the Wilcoxon signed rank test.
Results: 64 patients met our inclusion criteria and had adequate follow-up data available. The mean BMI was 57 kg/m(2) (range 36.6- 85.4 kg/m(2)), the female to male ratio was 4:1 (51:13), and the mean age was 44 years (range 27-64). The average monthly medication expenditure was reduced from US dollars 317 (SEM 47.25, range US dollars 23.12-US dollars 1801.19) preoperatively, to US dollars 135 (SEM 35.35, range US dollars 0.00-US dollars 1122.72) postoperatively. This reduction is significant (P <0.01).
Conclusion: Weight loss after RYGBP leads to a significant reduction in medication expenses. These medication savings offset the costs of the initial procedure and represent permanent financial savings for the patient and society.
Databáze: MEDLINE
Externí odkaz: